Top Markets
Coin of the day
MaaT Pharma S.A. MaaT Pharma S.A.

MaaT Pharma S.A.

MAAT
株式のランク #23616
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on... MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.
株価
$3.78
最終同期: 2026-08-21
時価総額
$71.20M
変化(1日)
2.24%
変化(1年)
-43.37%
FR
取引 MaaT Pharma S.A. (MAAT)

カテゴリー

MaaT Pharma S.A.(MAAT)の配当利回りの履歴
MaaT Pharma S.A.(銘柄コード: MAAT)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
MaaT Pharma S.A.(MAAT)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)